D

Day One Biopharmaceuticals Inc
NASDAQ:DAWN

Watchlist Manager
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Watchlist
Price: 12.69 USD -0.78% Market Closed
Market Cap: 1.3B USD
Have any thoughts about
Day One Biopharmaceuticals Inc?
Write Note

Day One Biopharmaceuticals Inc
Other Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Day One Biopharmaceuticals Inc
Other Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
D
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Other Current Assets
$8.9m
CAGR 3-Years
90%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Other Current Assets
$4.6B
CAGR 3-Years
2%
CAGR 5-Years
17%
CAGR 10-Years
-1%
Gilead Sciences Inc
NASDAQ:GILD
Other Current Assets
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Other Current Assets
$3.1B
CAGR 3-Years
7%
CAGR 5-Years
-2%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Other Current Assets
$449.2m
CAGR 3-Years
-1%
CAGR 5-Years
21%
CAGR 10-Years
27%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Other Current Assets
$412m
CAGR 3-Years
-5%
CAGR 5-Years
13%
CAGR 10-Years
14%
No Stocks Found

Day One Biopharmaceuticals Inc
Glance View

Market Cap
1.3B USD
Industry
Biotechnology

Day One Biopharmaceuticals Inc. emerged on the healthcare scene with a mission deeply rooted in a poignant reality: the need for tailored cancer treatments for children. Named symbolically to reflect the fresh start they aspire to offer to young patients, Day One focuses on developing and commercializing targeted therapies specifically for pediatric cancer, a field historically overlooked by the larger pharmaceutical industry. The company employs innovative drug development strategies, utilizing molecular targeted therapy—a precise approach that zeroes in on cancer cells while sparing healthy ones. This methodology not only underscores their commitment to efficacy and safety but also positions them as pioneers in an area rife with unmet medical needs. Fundamentally, the company generates its revenue through the successful commercialization of its therapies. It channels resources into robust clinical trials to demonstrate the efficacy and safety of its drugs, seeking regulatory approvals as key milestones. Licensing deals also play a crucial role in its business model, as partnerships with larger pharmaceutical firms enable Day One to expand its reach and scale. This strategic blending of in-house development and external alliances allows Day One to navigate the complex biopharmaceutical landscape efficiently, driving both innovation and financial sustainability. As they continue to advance their pipeline, the company aims to reshape pediatric oncology, demonstrating that profitable ventures can indeed be built around noble societal missions.

DAWN Intrinsic Value
13.54 USD
Undervaluation 6%
Intrinsic Value
Price
D

See Also

What is Day One Biopharmaceuticals Inc's Other Current Assets?
Other Current Assets
8.9m USD

Based on the financial report for Dec 31, 2023, Day One Biopharmaceuticals Inc's Other Current Assets amounts to 8.9m USD.

What is Day One Biopharmaceuticals Inc's Other Current Assets growth rate?
Other Current Assets CAGR 3Y
90%

Over the last year, the Other Current Assets growth was 59%. The average annual Other Current Assets growth rates for Day One Biopharmaceuticals Inc have been 90% over the past three years .

Back to Top